Morgan Stanley has a “buy” rating on the stock. Boston Scientific has a 52-week low of $11.10 and a 52-week high of $16.84, according to the report.
More articles on gastroenterology:
Check-Cap IPO unites to trade separately from March 18 onwards
Akron General Partners Physician Group adds Dr. Jeffery Neher
Actavis completes $70.5B Allergan acquisition
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.